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Abstract
Background Target volume definition of the primary tumor in esophageal cancer is usually based on computed tomog-
raphy (CT) supported by endoscopy and/or endoscopic ultrasound and can be difficult given the low soft-tissue contrast
of CT resulting in large interobserver variability. We evaluated the value of a dedicated planning [F18] FDG-Positron
emission tomography/computer tomography (PET/CT) for harmonization of gross tumor volume (GTV) delineation and
the feasibility of semiautomated structures for planning purposes in a large cohort.
Methods Patients receiving a dedicated planning [F18] FDG-PET/CT (06/2011–03/2016) were included. GTV was delin-
eated on CT and on PET/CT (GTVCT and GTVPET/CT, respectively) by three independent radiation oncologists. Interobserver
variability was evaluated by comparison of mean GTV and mean tumor lengths, and via Sørensen–Dice coefficients (DSC)
for spatial overlap. Semiautomated volumes were constructed based on PET/CT using fixed standardized uptake val-
ues (SUV) thresholds (SUV30, 35, and 40) or background- and metabolically corrected PERCIST-TLG and Schaefer
algorithms, and compared to manually delineated volumes.
Results 45 cases were evaluated. Mean GTVCT and GTVPET/CT were 59.2/58.0ml, 65.4/64.1ml, and 60.4/59.2ml for
observers A–C. No significant difference between CT- and PET/CT-based delineation was found comparing the mean
volumes or lengths. Mean Dice coefficients on CT and PET/CT were 0.79/0.77, 0.81/0.78, and 0.8/0.78 for observer
pairs AB, AC, and BC, respectively, with no significant differences. Mean GTV volumes delineated semiautomatically
with SUV30/SUV35/SUV40/Schaefer’s and PERCIST-TLG threshold were 69.1/23.9/18.8/18.6 and 70.9ml. The best
concordance of a semiautomatically delineated structure with the manually delineated GTVCT/GTVPET/CT was observed for
PERCIST-TLG.
Conclusion We were not able to show that the integration of PET/CT for GTV delineation of the primary tumor resulted
in reduced interobserver variability. The PERCIST-TLG algorithm seemed most promising compared to other thresholds
for further evaluation of semiautomated delineation of esophageal cancer.
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GEJ Cancer of the esophagogastric junction
GTV Gross tumor volume
GTVCT Gross tumor volume derived by CT
GTVPET/CT Gross tumor volume derived by PET/CT
IMRT Intensity-modulated radiotherapy
LoD Length of disease
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Fig. 1 Manual gross tumor
volume (GTV) delineation by
three observers (yellow, blue,
green) a on CT alone axial and
b sagittal; c GTV delineation




PTV Planning target volume
SPSS Statistical Package for Social Sciences
SUV Standardized uptake values
SUVmax Maximum standardized uptake value
VMAT Volumetric modulated arc therapy
Introduction
Radiation therapy is a cornerstone of the multimodality
treatment of locally advanced esophageal cancer [1, 2], ei-
ther as definitive chemoradiotherapy (CRT) or as preop-
erative CRT based on randomized controlled trials [3, 4].
While dose and fractionation concepts have remained rela-
tively constant, a considerable shift towards smaller target
volumes resulting in less toxicities has taken place over the
past decades. For example, the landmark trial RTOG 85–11,
which established concurrent CRT as the standard of care
for inoperable locally advanced esophageal cancer in the
early 90s, had used generous margins for elective nodal ir-
radiation as well as for a tumor bed boost [3]. In contrast,
the CROSS trial establishing the role of neoadjuvant CRT
more than a decade later introduced much smaller margins
including the GTV without any elective nodal irradiation
[4]. Similar (smaller) approaches have been proposed re-
cently by the Expert Consensus Contouring guidelines by
Wu et al. [5]. Therefore, accurate delineation of gross tumor
volume becomes more crucial, especially when combined
with the steep dose gradients achieved by modern radiation
techniques like intensity-modulated radiation therapy.
CT-based target delineation still represents the stan-
dard of care for radiation therapy treatment planning of
esophageal cancer patients, although precise definition of
the exact tumor boundaries can be difficult, especially in the
cranio-caudal direction but also towards directly adjacent
mediastinal structures. PET/CT offers some general advan-
tages compared to CT as it adds metabolic to anatomic
information, thus enabling a more precise differentiation
between vital tumor volume and surrounding structures.
Therefore, it has been extensively used in diagnosis, stag-
ing, and response assessment of cancer patients [6–8].
For radiation therapy planning, PET/CT seems particularly
interesting if performed in the treatment position and has
been shown to impact target volumes, for example, in
lung cancer, head and neck cancer, prostate cancer, and
brain tumors [9–12]. While the role of PET/CT in assess-
ment of lymph node involvement of esophageal cancer is
well established [13, 14], its role in target delineation of
the primary tumor is more controversial. Several studies
have reported conflicting results [6, 15–20], which may
have been affected by small sample sizes and different
methods of PET/CT-based contouring. While most studies
used visual interpretation of PET/CT images, others pro-
moted either fixed absolute SUV thresholds, like SUV2.5
or percentages of SUVmax such as SUV20, with varying
results [15, 16, 21]. Recently, our group reported even more
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Fig. 2 Manual gross tumor
volume (GTV) delineation
on a CT alone, b fused
[F18] FDG-PET/CT, c GTVCT
(yellow), d GTVPET/CT (blue),
e matched GTVCT (yel-
low), GTVPET/CT (blue), and
PERCIST-TLG (red), f PER-
CIST-TLG (red) semiautomated
contour
Fig. 3 Sørensen–Dice coefficient
complex background- and metabolically corrected values
such as the PERCIST-TLG algorithm as most promising in
a study including solid tumors of different origin [10].
Therefore, the purpose of the current study was to eval-
uate the value of additional PET/CT information on target
delineation of gross tumor volume of the primary tumor in
esophageal cancer patients in a larger patient cohort. The
first part was designed to answer the question of whether
the addition of visually interpreted PET/CT information to
the standard CT-based planning approach can result in re-
duced interobserver variability for manual GTV definition
taken as a surrogate for more accurate delineation. The sec-
ond part should answer the question of whether semiauto-
matic delineation methods may help in the harmonization




We retrospectively identified 57 consecutive patients who
had been treated with neoadjuvant or definitive radiation
therapy for non-metastatic esophageal cancer at our depart-
ment with a dedicated PET/CT for treatment planning avail-
able from 6/2011 to 3/2016. Of these patients, 12 had to be
excluded from the analysis, 6 for low [F18] FDG activity
(maximum standardized uptake value, SUVmax, <4), 2 scans
showed artifacts from metallic material in the region of the
tumor, and in 4 patients the software was unable to generate
a semiautomated structure set. Therefore, 45 patients were
included in the current study.
[F18] FDG-PET/CT
All included patients had received a dedicated planning
[F18] FDG-PET/CT in supine treatment positioning prior to
clinical treatment. Whole-body [F18] FDG-PET/CT scans
were acquired from the base of the skull to the proximal
femora (GE Discovery 690, General Electric, Munich, Ger-
many). Patients fasted for at least 6 h before PET/CT images
were acquired. Emission scans were initiated after a median
uptake time of 60min (range 46–113min) following intra-
venous administration of 20mg of furosemide, 20mg of
butylscopolamine, and [F18] FDG (mean activity 246 MBq,
range: 184–322 MBq). Diagnostic CT images using intra-
K
Strahlenther Onkol
Fig. 4 a CT alone, b fused
[F18] FDG-PET/CT, c SUV30
semiautomated contour (yellow),
d PERCIST semiautomated
contour (red), e matched SUV30
(yellow) and PERCIST (red)
venous contrast agent in portal venous phase were acquired
in suitable patients. PET images were reconstructed using
ordered subset expectation maximization (OSEM)-based al-
gorithms (VUE point FX).
Manual gross tumor volumedelineation
Primary tumor delineation was performed by three indepen-
dent experienced radiation oncologists without prior knowl-
edge of the images or the clinically used target volumes both
on PET/CT and CT only. Scans were blinded; only base-
line clinical information including TNM stage and tumor
extent derived by endoscopy was provided. The radiation
oncologists were asked to define the GTV of the primary
tumor and include affected lymph nodes only if directly
adjacent to the main tumor, since these lymph nodes would
also be included in the semiautomatically delineated GTVs.
No delineation of nodal volumes (except the above men-
tioned) or clinical target volumes was performed. GTV of
the primary tumor was defined for all studies by each radi-
ation oncologist first on CT scans only (GTVCT). To avoid
bias in contouring of the PET/CT-based GTV, definition
of the respective GTVs on CT including the PET informa-
tion (GTVPET/CT) was done with delay and in random order
(Fig. 1). For the manually delineated GTVPET/CT, no fixed
SUV threshold was provided (visual interpretation; Fig. 2).
Interobserver variability
Mean tumor volumes and mean tumor lengths of the three
observers were calculated per patient for each modality (CT
and PET/CT) and compared in non-parametric paired anal-
ysis using the Wilcoxon test. To assess geometrical differ-
ences, Sørensen–Dice coefficients (Fig. 3) were computed
for all three pair of observers and for each modality. Mean
dice coefficients of the three observer pairs were calculated
for each patient and each modality and compared by the
Wilcoxon test.
Semiautomated gross tumor volume delineation
Semiautomated GTV delineation based on the given
[F18] FDG-PET was performed using a dedicated soft-
ware package (Hybrid Viewer, Hermes Medical Solutions,
Stockholm, Sweden). Semiautomated GTVs were defined
for a set of standardized uptake values (SUV) derived
from the maximal SUV (SUVmax): SUV30, SUV35, and
SUV40 defined as 30, 35, and 40% of SUVmax. PERCIST-
TLG threshold was determined in analogy to the PERCIST
criteria based on normal [F18] FDG background activity
in a standardized 15ml VOI in the right hepatic lobe as
described by Niyazi et al. [10]. Schaefer’s threshold was
calculated by using the formula TS= axSUV70+ bxBG as
described by Schaefer et al. ([22]; Fig. 4).
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SCC squamous cell carcinoma, GEJ gastroesophageal junction,
RT radiation therapy, SUV standardized uptake value
Concordance of semiautomatically delineated GTVs
andmanually delineated GTVs
The semiautomatically delineated GTVs of the different
methods were compared with the mean manually delin-
eated GTVCT and GTVPET/CT of the three observers by the
Wilcoxon test.
Dice coefficients were computed for each patient for
the semiautomatically delineated GTVs of every method
with the manually delineated GTVs of every modality of
the three observers separately. Mean Dice coefficients were
then calculated for every observer and compared descrip-
tively between the different methods of semiautomated de-
lineation.
Statistical analysis
Statistical analysis was performed using the Statistical
Package for Social Sciences (SPSS, version 26, SPSS Inc,
Chicago, IL, USA). For descriptive analysis of patient
characteristics and volumes, mean values and ranges were
used. GTVs and tumor lengths were compared using the
Wilcoxon test after testing for normality by the Kolgo-
morov–Smirnov test failed for the majority of parameters.
Results
A total of 45 [F18] FDG-PET/CT datasets of 45 patients
were analyzed. Of these, 39 patients had SCC and 5 had his-
tologically proven adenocarcinoma of the esophagus. Tu-
mors were localized in the cervical (7patients), upper tho-
racic (16patients), middle thoracic (13patients), and lower
thoracic (9patients) part of the esophagus. Of all patients,
16 had no evidence of lymph node involvement while 29 pa-
tients had positive lymph nodes on [F18] FDG-PET/CT.
Detailed Patient characteristics are listed in Table 1.
Interobserver variability
Mean primary GTV volumes of all patients based on man-
ual delineation on CT and PET/CT for each observer were
59.2 and 58.0ml for observer A, 65.4 and 64.1ml for ob-
server B, and 60.4 and 59.22ml for observer C. No sig-
nificant difference between CT- and PET/CT-based delin-
eation was found upon comparing the mean volumes of all
three observers per patient on each modality (60.4ml vs.
59.22ml, p= 0.53). Mean tumor length of all patients based
on CT and PET/CT for each observer were 8.1 and 8.1cm
for observer A, 8.3 and 7.6cm for observer B, and 7.9 and
7.6cm for observer C. Again, no significant difference be-
tween CT- and PET/CT-based delineation was found upon
comparing the mean tumor lengths of all three observers
per patient on each modality (p= 0.11), see Table 2.
Mean DICE coefficients of all patients on CT and
PET/CT were 0.79 and 0.77 for observer pair AB, 0.81 and
0.78 for observer pair AC, and 0.8 and 0.78 for observer
pair BC. No significant difference was found between the
mean Dice coefficients of all observer pairs per patient
between CT- and PET/CT-based delineation (Table 2).
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Table 2 Comparison of manually delineated volumes of different modalities (GTVCT vs. GTVPET/CT)
Three observers Three observers Three observer pairs
Patient Mean GTV Mean GTV Mean length Mean length Mean Dice Mean Dice
Number CT (ccm) PET/CT (ccm) CT (cm) PET/CT (cm) CT PET/CT
1 488.15 488.57 14.83 15.27 0.82 0.86
2 27.97 32.06 5.33 6.07 0.86 0.82
3 182.09 175.51 16.83 16.17 0.89 0.87
4 35.38 38.25 7.03 6.67 0.82 0.87
5 65.04 64.16 8.63 9.20 0.85 0.83
6 41.66 50.73 5.37 5.07 0.79 0.79
7 21.41 18.35 4.03 3.63 0.81 0.81
8 55.57 53.23 9.07 9.70 0.86 0.89
9 25.03 21.96 7.80 5.13 0.86 0.81
10 73.93 57.25 11.40 7.23 0.79 0.81
11 13.98 16.07 4.50 4.20 0.78 0.79
12 24.14 23.00 5.60 5.23 0.65 0.69
13 26.57 27.20 7.30 6.67 0.84 0.81
14 27.72 29.61 6.83 6.53 0.80 0.79
15 7.50 13.82 2.83 4.23 0.76 0.55
16 30.64 31.92 5.60 6.10 0.86 0.88
17 37.98 37.93 7.33 6.57 0.90 0.82
18 17.57 21.20 6.30 8.53 0.76 0.55
19 24.57 28.27 6.90 7.47 0.78 0.77
20 11.87 12.44 5.07 4.43 0.78 0.63
21 39.53 39.84 7.20 6.83 0.82 0.78
22 101.04 128.66 10.83 12.67 0.79 0.80
23 7.50 6.41 4.67 3.00 0.82 0.86
24 40.62 29.49 7.13 5.53 0.77 0.72
25 13.99 16.62 4.57 5.13 0.79 0.74
26 33.47 33.52 7.43 6.97 0.54 0.49
27 11.66 9.87 5.10 4.43 0.48 0.61
28 66.96 69.06 9.17 9.37 0.83 0.79
29 160.32 165.15 10.57 9.17 0.84 0.89
30 37.48 24.96 7.00 4.43 0.86 0.87
31 23.34 18.28 7.33 5.50 0.81 0.68
32 188.17 173.60 12.50 12.17 0.87 0.88
33 137.50 132.84 12.33 10.87 0.85 0.90
34 40.20 33.94 8.77 6.30 0.87 0.84
35 23.65 24.74 3.80 4.13 0.87 0.82
36 30.00 25.19 6.13 4.87 0.87 0.86
37 27.56 26.71 6.00 7.07 0.83 0.74
38 138.39 107.23 21.60 22.33 0.81 0.78
39 65.53 90.83 7.17 6.47 0.76 0.72
40 3.79 7.98 3.30 4.00 0.64 0.67
41 55.96 54.61 7.53 7.80 0.88 0.86
42 81.89 53.03 11.90 10.57 0.68 0.84
43 57.95 54.82 9.80 11.70 0.85 0.81
44 69.44 74.51 9.33 9.47 0.83 0.88
45 22.46 21.53 6.87 6.20 0.85 0.82
Mean 60.38 59.22 7.93 7.58 0.80 0.78
Min 3.79 6.41 2.83 3.00 0.48 0.49
Max 488.15 488.57 21.60 22.33 0.90 0.90
K
Strahlenther Onkol
Table 3 Volume comparison of manually and semiautomatically
delineated GTVsp= 0.826
Mean GTVCT Mean GTVPET/CT
GTV SUV30 p< 0.001 p< 0.001
GTV SUV35 p< 0.001 p< 0.001
GTV SUV40 p< 0.001 p< 0.001
GTV Schaefer p< 0.001 p< 0.001
GTV PERCIST-TLG p= 0.722 –
Concordance of manually and semiautomatically
delineated GTVs
The mean SUVmax for the entire cohort was 17.3 (range
7.3–51.5). Mean values for SUV30, SUV35, SUV40,
Schaefer’s threshold, and PERCIST-TLG threshold were
5.3 (2.2.–15.5), 6.1 (2.6–18.1), 6.9 (2.9–20.6), 7.0 (3.4–19),
and 3.0 (1.4–4.3), respectively. The corresponding mean
GTV volumes for SUV30, SUV35, SUV40, Schaefer’s
threshold, and PERCIST TLG threshold were 69.1ml
(2.6–22.5), 23.9ml (1.3–16.0), 18.8ml (0.7–14.1), 18.6ml
(0.7–12.6), and 70.9ml (2.3–35.2), respectively.
Comparison of the semiautomatically delineated GTVs
with the mean manually delineated GTVCT and GTVPET/CT
of all observers resulted in significant differences for all
thresholds except for the comparison of PERCIST-TLG
threshold with GTVCT or GTVPET/CT (Table 3).
Mean Dice coefficients per observer were calculated for
every semiautomatically delineated GTV with both man-
ually delineated GTVCT and GTVPET/CT. The best concor-
dance with the manually delineated GTV CT and GTV
PET/CT was observed for PERCIST-TLG threshold (mean
Dice 0.57–0.6 with GTV CT and 0.61–0.65 for PET/CT;
Table 4).
The mean Dice coefficients per observer comparing
the manually delineated GTVCT with the GTVPET/CT were
0.77–0.8 (Table 5).
Discussion
Adequate delineation of the gross tumor volume of the pri-
mary tumor is a prerequisite for successful radiation treat-
ment in general [21]. This is particularly important for





Obs. A Obs. B Obs. C Mean Obs. A Obs. B Obs. C Mean
SUV30 0.54 0.51 0.55 0.53 0.6 0.54 0.61 0.58
SUV35 0.52 0.49 0.53 0.51 0.57 0.51 0.59 0.56
SUV40 0.48 0.44 0.48 0.47 0.51 0.46 0.54 0.5
PERCIST-TLG 0.59 0.57 0.6 0.59 0.64 0.61 0.65 0.63
Schaefer 0.46 0.43 0.46 0.45 0.49 0.44 0.52 0.48
Table 5 Mean Dice similarity coefficient of manually delineated GTV
CT vs. GTV PET/CT per observer
Observer A Observer B Observer C
Mean 0.77 0.78 0.80
Minimum 0.46 0.46 0.42
Maximum 0.91 0.91 0.95
the use of modern radiation techniques, with a high level
of dose conformity (like IMRT or particle therapy) lead-
ing to a higher risk of suboptimal tumor coverage [21] in
case of inadequate delineation. CT-based delineation in-
corporating information from other diagnostic modalities
like endoscopy or endoscopic ultrasound is currently the
standard approach for delineating the GTV of the primary
tumor in esophageal cancer. However, the discriminative
value of CT regarding tumor volume and surrounding nor-
mal esophageal or mediastinal tissue is often limited, as is
the ability to relate spatial information from endoscopy or
EUS to the planning CT. As most esophageal cancers show
increased FDG uptake [21], especially in locally advanced
cases which are typically treated with radiation therapy, it
seemed reasonable to evaluate the incorporation of PET/CT
into target volume delineation. Several groups have there-
fore investigated PET/CT-based delineation with regard to
various endpoints with different methodologies (summa-
rized in Table 6), thus (not surprisingly) reporting conflict-
ing results [6, 15–20].
Direct correlation of imaging information with patholog-
ical specimens is the gold standard to test the validity of an
imaging method and has also been studied in esophageal
cancer [24–26]. However, this approach requires upfront
surgery, which is not the preferred treatment option, es-
pecially for locally advanced esophageal cancer in the era
of neoadjuvant chemo- or chemoradiation. Analysis of in-
tra- and interobserver variability may serve as a surrogate
based on the assumption that lower variability represents
more accurate delineation [21].
Therefore, the first aim of our study was to evaluate if the
addition of PET/CT to the standard approach based on CT
combined with information from endoscopy reduces the in-
terobserver variability of GTV definition regarding the pri-
mary tumor in a larger cohort than previously reported. We
therefore compared the interobserver variability of three
independent observers delineating the primary tumor in
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Table 6 Overview on available literature





28 EC Concordance indices GTV,
CTV, and PTV
None CT+EUS No statistically significant difference
in concordance indices
No impact on observer variation
Vali et al.
[16]






CT+EUS SUV2.5 yields the highest confor-
mality index and best approximates





Influence of uptake hetero-
geneity on tumor delin-
eation
SUV40%; SUV2.5 CT Larger GTV delineation difference




20 EC Tumor volume, tumor






CT+ clips CT+ clips as “gold standard,” no












29 EC GTVtumor and GTVnode
comparison of volume and
tumor length
None CT No significant difference in volume
of GTVtumor but in GTVnode
Toya et al.
[20]
10 CEC Interobserver variation None ceCT, barium
esophagogram,
EUS
PET/CT may increase consistency
in GTV delineation in patients with
CEC
EC esophageal cancer, SCEC squamous cell esophageal cancer, CEC cervical esophageal cancer, EUS endoscopic ultrasound, VR volume ratio,
CI conformity index, DI degree of inclusion
45 cases either with CT or PET/CT with regard to volume
and length of corresponding GTVs. Surprisingly, we were
not able to detect significant differences between the delin-
eated volumes or the tumor lengths between the two meth-
ods. Moreover, concordance between the observers mea-
sured by DICE coefficients was not significantly different
between the methods, with the absolute values even favor-
ing the CT-based approach (mean Dice coefficient 0.8 vs.
0.78 for CT vs. PET/CT based delineation). These results
are in line with the findings of several smaller studies using
similar approaches. For example, Scheurs et al. [15] evalu-
ated 28 patients comparing CT- and PET/CT-based delin-
eation by three observers using a concordance index and
reported no significant differences. Nowee et al. [6] evalu-
ated 6 cases with 20 observers in a nationwide study in the
Netherlands using a conformity index and similarly found
no significant reduction in interobserver variability between
the two modalities. In contrast, Toya et al. [20] described
a significantly reduced interobserver variability for PET/CT
compared to CT measured by conformality index in their
cohort of 10 patients with cervical esophageal cancer de-
lineated by five observers, with significantly smaller GTVs
based on PET/CT imaging. Similarly, Vesprini et al. [27]
reported a small but significant reduction in intraobserver
variability for the PET/CT-based approach in their study
of 10 patients with gastroesophageal cancer. In summary,
a benefit of using PET/CT for delineation of the primary
tumor volume remains questionable based on the available
literature, especially given the negative results of the larger
studies including ours. These recent findings confirm the re-
sults of a systematic review published by Mujis et al. [21] in
2010, which similarly concluded that the (at that time more
limited) available data did not provide sufficient evidence
that the integration of PET/CT will necessarily improve the
accuracy of GTV delineation in patients with esophageal
cancer.
However, these findings should not be misinterpreted re-
garding PET/CT as a useless tool per se in radiation ther-
apy planning for esophageal cancer. Several groups have
described the superiority of PET/CT compared to conven-
tional CT in the detection and delineation of affected lymph
nodes, which may lead to substantial changes in nodal
GTVs and CTVs [13, 19, 28–30], although inconsistent data
from imaging studies on the improvement of sensitivity and
specificity of PET/CT compared to other staging modalities
exist [21, 31]. Recently, a retrospective analysis of 145 pa-
tients treated with neoadjuvant or definitive chemoradiation
for esophageal cancer compared patients with or without
PET/CT staging with regard to outcome [31]. They found
a significantly improved locoregional recurrence-free sur-
vival in patients staged by PET/CT with a trend even to
improved survival probably based on more accurate target
delineation and consequently improved treatment efficacy
[31]. Moreover, PET/CT clearly improves the detection of
distant metastases compared to conventional CT [32, 33]
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and therefore seems crucial for adequate patient selection
for localized therapies like radiation [31, 33].
Some reasons for the lack of improvement by the addi-
tion of PET/CT for delineation of the primary GTV might
be simply technical issues. Delineated volumes based on
PET/CT may vary extensively based on the contouring
method using the metabolic information. Two major types
of contouring methods exist, either using visual interpreta-
tion (with or without source-to-background correction) or
different fixed SUV thresholds. Visual interpretation, which
was used in most of the cited studies, is highly observer
dependent as image representation can be controlled by
changing window widths or window levels, resulting in dif-
ferent visible tumor volumes [21]. On the other hand, SUV
as a semiquantitative parameter can be affected by many
parameters such as patient preparation, scan acquisition,
image reconstruction, and data analysis, which may result
in considerable differences in SUV outcome even though
most of these effects are small [21]. Nevertheless, semiau-
tomated delineation methods based on fixed thresholds may
be helpful in the harmonization of GTV volume definition.
The second aim of our study was therefore to evaluate
different SUV-dependent methods with regard to their con-
cordance with manually delineated GTV volumes. Different
SUV-based thresholds have been analyzed in the past, ei-
ther based on fixed absolute values like SUV2.5 [16], based
on relative SUV values like SUV30 which represents 30%
of the SUVmax of the individual patient [16, 18], or even
more complex thresholds including corrections for back-
ground or metabolic activity [10]. As thresholds based on
absolute values might be additionally influenced by indi-
vidual patient parameters such as body weight and blood
glucose levels, we decided to evaluate relative SUV values
(SUV30, 35, and 40). Based on our initial experience, we
included the background- and metabolically corrected PER-
CIST-TLG [10] and Schaefer’s algorithm [22]. Our previ-
ous work had described especially the PERCIST TLG algo-
rithm as promising in an analysis including 20 patients with
solid tumors including 5 suffering from esophageal cancer
[10].
As assumed, we observed considerable differences in
the GTV volumes derived from semiautomated delineation
with different thresholds, which varied distinctly not only
between each other but also compared to the manually de-
lineated GTVs based on CT and PET/CT using visual in-
terpretation. Indeed, all thresholds used resulted in signif-
icantly different volumes compared to the mean manually
delineated GTVs of the three observers both for CT and
PET/CT, except the PERCIST-TLG algorithm.
Regarding the calculated Dice coefficients for the differ-
ent semiautomatically delineated volumes with the manu-
ally delineated volumes of the three observers, we found
the highest mean Dice coefficients for the PERCIST-TLG
algorithm with manually derived CT (mean Dice coeffi-
cient 0.59) as well as PET/CT GTVs (mean Dice coefficient
0.63). However, even the best semiautomated volume (PER-
CIST-TLG) had a lower concordance with both manually
derived GTVs (CT vs. PET/CT) than the GTVPET/CT based
on visual interpretation with the GTVCT for every observer
(mean Dice coefficient 0.79), indicating a still suboptimal
result.
One major drawback for the use of semiautomatically
delineated volumes is the common practice of radiation on-
cologists to always include the whole circumference of the
esophagus into the GTV even if visible primary tumor is
present only at one side of the esophageal wall. In con-
trast, all software-based algorithms will contour volumes
strictly restricted to detected tumor, which sometimes result
in GTVs not covering the whole esophageal circumference
(as illustrated in Fig. 4). This issue should be addressed in
the design of further studies, either by adding a step to auto-
mated contouring to always include the whole esophageal
structure in the corresponding CT slice if tumor is auto-
matically detected, or in advising the human observers to
strictly contour only the visible tumor regardless of the ad-
jacent esophageal structure.
Our study has some limitations: It is of retrospective na-
ture and therefore may not serve as a confirmative but rather
as a hypothesis-generating study regarding at least the de-
sign of future studies. Due to the high number of included
patients, we decided to limit the number of observers to
three, which seems to be the possible minimum (although
studies with larger numbers of observers provided similar
results). As we focused on primary gross tumor volume, no
insights into the possible value of PET/CT for lymph node
delineation, clinical target volume definition, or detection
of distant metastases can be given. Finally, the common
practice of radiation oncologists to include the whole cir-
cumference of the esophagus into the GTV even if visible
tumor (on imaging) is present only at parts of the circum-
ference makes direct comparisons to semiautomatically de-
tected volumes difficult.
Conclusion
In summary, we were not able to show that the integra-
tion of PET/CT for GTV delineation of the primary tumor
in esophageal cancer patients resulted in reduced interob-
server variability in a large cohort of patients. Moreover,
the evaluated semiautomatically delineated GTVs based on
fixed SUV thresholds did not correlate well with the man-
ually derived GTV volumes based either on CT or visually
interpreted PET/CT. Nevertheless, we found that the most
promising algorithms for further evaluation of semiauto-
matically delineated volumes probably seem to be back-
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ground- and metabolically corrected algorithms like PER-
CIST-TLG, which showed the highest concordance with the
manually derived GTVs of all evaluated methods. However,
our findings should not be misinterpreted regarding the gen-
eral value of PET/CT for staging and treatment planning in
esophageal cancer patients based on the possible advantages
for detection of lymph nodes, including definition of clin-
ical target volumes or the detection of distant metastases.
Further studies regarding primary GTV definition should
account for general differences between human and semi-
automated contouring with regard to inclusion of the whole
circumference of tumor-bearing slices of the esophageal
structure.
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